MedTrace Logo

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

NCT06584071 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-12-16

No results posted yet for this study

Summary

This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.

Conditions

Interventions

DRUG

PM8002

PM8002 via IV infusion, Q3W

DRUG

PM1009

PM8002 via IV infusion, Q3W

DRUG

atezolizumab

atezolizumab,1200mg, via IV infusion, Q3W

DRUG

bevacizumab

bevacizumab,15mg/kg, via IV infusion, Q3W

Sponsors & Collaborators

  • Biotheus Inc.

    lead INDUSTRY

Principal Investigators

  • Jia Fan · Zhong Shan Hospital, Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-10-31
Completion
2027-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06584071 on ClinicalTrials.gov